Autologous Segment to Dominate North America Skin Graft Market during 2020–2028

According to a new market research study on “North America Skin Graft Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Graft thickness, Equipment, Application, and End user,” is expected to reach US$ 664.40 million by 2028 from US$ 426.44 million in 2021. The market is estimated to grow at a CAGR of 6.5% from 2021 to 2028. The report provides trends prevailing in the North America skin graft market along with the drivers and restraints pertaining to the market growth.Increasing number of burn injuries is the major factor driving the growth of the North America skin graft market. However, high cost of skin grafting procedures hinders the growth of North America skin graft market.

The outbreak of the COVID-19 pandemic has adversely affected the non-healing or chronic wound management and regenerative medicine market. Various people across the North American region are affected. For instance, the US is a highly affected country in the North American regions. The effect of the corona is mild in adults; however, it is adverse in older people. The infection of corona among older people has resulted in severe complications and has accounted for a higher number of deaths in the country. In addition, skin cancer is majorly seen in older people in US and 1 in 5 Americans will develop skin cancer by the age of 70. More than 2 people die of skin cancer in the U.S. every hour. Therefore, regular dressing and proper care is required to prevent chronic cases of infection and health condition. Due to the outbreak of COVID-19, various hospitals were engaged in treating the affected people. Additionally, various wound care centers are located in hospitals. Hence, majority of the patients did not receive wound care. ~ 1 in 4 patients is able to receive wound care, and it is expected that there are nearly 6.7 million people across the US those are waiting for the wound treatment. Researchers evaluated the stability of SARS-CoV-2 and influenza A virus (IAV), mixed with culture medium or upper respiratory mucus, on human skin surfaces, and the dermal disinfection effectiveness of 80 per cent (w/w) ethanol against SARS-CoV-2 and IAV. Researchers conducted lab experiments using cadaver skin that would otherwise have been used for skin grafts to avoid possibly infecting healthy volunteers. The outbreak of COVID-19 has impact skin graft market profoundly by affecting the quality care.

The market for skin graft market is segmented into product, graft thickness, equipment, application, end user and country. Based on product, the market is segmented into autologous, allogeneic, xenogeneic, prosthetic, and isogeneic. In 2020, the autologous segment held the largest share of the market. Based on graft thickness, the market is divided into split-thickness, full-thickness and composite graft. In 2020, the split thickness segment held the largest share of the market. Based on equipment, the market is segmented into dermatome, general surgical instruments, consumables, and others. In 2020, the dermatome segment held the largest share of the market. Based on application, the market is segmented into burns, extensive wound, skin cancer, and others. In 2020, the burns segment held the largest share of the market. Based on end user, the market is segmented into ambulatory surgical centers, hospitals and dermatology clinics. In 2020, the hospitals segment held the largest share of the market. Similarly, based on country, the market is bifurcated into US, Canada, and Mexico. US contributed a substantial share in 2020. 

AVITA Medical; B. Braun Melsungen AG; Integra Life Sciences Corporation; MiMedx; Nouvag AG; Organogenesis Inc; Smith & Nephew; Tissue Regenix Group; Zimmer Biomet; are among the leading companies in the North America skin graft market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, MiMedx Group, Inc. launched EpiCord Expandable, the latest advancement in its portfolio of products. At the core of this technology is EpiCord, which has demonstrated clinical efficacy in the treatment of diabetic foot ulcers.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com